230 related articles for article (PubMed ID: 33203876)
21. B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models.
Huang D; Abbott RK; Havenar-Daughton C; Skog PD; Al-Kolla R; Groschel B; Blane TR; Menis S; Tran JT; Thinnes TC; Volpi SA; Liguori A; Schiffner T; Villegas SM; Kalyuzhniy O; Pintea M; Voss JE; Phelps N; Tingle R; Rodriguez AR; Martin G; Kupryianov S; deCamp A; Schief WR; Nemazee D; Crotty S
Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22920-22931. PubMed ID: 32873644
[TBL] [Abstract][Full Text] [Related]
22. Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.
Mu Z; Haynes BF; Cain DW
Curr Opin Virol; 2021 Dec; 51():172-178. PubMed ID: 34742037
[TBL] [Abstract][Full Text] [Related]
23. Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis.
Dai K; He L; Khan SN; O'Dell S; McKee K; Tran K; Li Y; Sundling C; Morris CD; Mascola JR; Karlsson Hedestam GB; Wyatt RT; Zhu J
mBio; 2015 Nov; 6(6):e01375-15. PubMed ID: 26530382
[TBL] [Abstract][Full Text] [Related]
24. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.
Wiehe K; Bradley T; Meyerhoff RR; Hart C; Williams WB; Easterhoff D; Faison WJ; Kepler TB; Saunders KO; Alam SM; Bonsignori M; Haynes BF
Cell Host Microbe; 2018 Jun; 23(6):759-765.e6. PubMed ID: 29861171
[TBL] [Abstract][Full Text] [Related]
25. Broadly Neutralizing Antibodies against HIV: Back to Blood.
Dashti A; DeVico AL; Lewis GK; Sajadi MM
Trends Mol Med; 2019 Mar; 25(3):228-240. PubMed ID: 30792120
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.
Jardine JG; Kulp DW; Havenar-Daughton C; Sarkar A; Briney B; Sok D; Sesterhenn F; Ereño-Orbea J; Kalyuzhniy O; Deresa I; Hu X; Spencer S; Jones M; Georgeson E; Adachi Y; Kubitz M; deCamp AC; Julien JP; Wilson IA; Burton DR; Crotty S; Schief WR
Science; 2016 Mar; 351(6280):1458-63. PubMed ID: 27013733
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint modulation enhances HIV-1 antibody induction.
Bradley T; Kuraoka M; Yeh CH; Tian M; Chen H; Cain DW; Chen X; Cheng C; Ellebedy AH; Parks R; Barr M; Sutherland LL; Scearce RM; Bowman CM; Bouton-Verville H; Santra S; Wiehe K; Lewis MG; Ogbe A; Borrow P; Montefiori D; Bonsignori M; Anthony Moody M; Verkoczy L; Saunders KO; Ahmed R; Mascola JR; Kelsoe G; Alt FW; Haynes BF
Nat Commun; 2020 Feb; 11(1):948. PubMed ID: 32075963
[TBL] [Abstract][Full Text] [Related]
28. All eyes on the next generation of HIV vaccines: strategies for inducing a broadly neutralizing antibody response.
Ahlers JD
Discov Med; 2014 Apr; 17(94):187-99. PubMed ID: 24759623
[TBL] [Abstract][Full Text] [Related]
29. Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.
Escolano A; Steichen JM; Dosenovic P; Kulp DW; Golijanin J; Sok D; Freund NT; Gitlin AD; Oliveira T; Araki T; Lowe S; Chen ST; Heinemann J; Yao KH; Georgeson E; Saye-Francisco KL; Gazumyan A; Adachi Y; Kubitz M; Burton DR; Schief WR; Nussenzweig MC
Cell; 2016 Sep; 166(6):1445-1458.e12. PubMed ID: 27610569
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.
Moody MA; Yates NL; Amos JD; Drinker MS; Eudailey JA; Gurley TC; Marshall DJ; Whitesides JF; Chen X; Foulger A; Yu JS; Zhang R; Meyerhoff RR; Parks R; Scull JC; Wang L; Vandergrift NA; Pickeral J; Pollara J; Kelsoe G; Alam SM; Ferrari G; Montefiori DC; Voss G; Liao HX; Tomaras GD; Haynes BF
J Virol; 2012 Jul; 86(14):7496-507. PubMed ID: 22553329
[TBL] [Abstract][Full Text] [Related]
31. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.
Escolano A; Gristick HB; Abernathy ME; Merkenschlager J; Gautam R; Oliveira TY; Pai J; West AP; Barnes CO; Cohen AA; Wang H; Golijanin J; Yost D; Keeffe JR; Wang Z; Zhao P; Yao KH; Bauer J; Nogueira L; Gao H; Voll AV; Montefiori DC; Seaman MS; Gazumyan A; Silva M; McGuire AT; Stamatatos L; Irvine DJ; Wells L; Martin MA; Bjorkman PJ; Nussenzweig MC
Nature; 2019 Jun; 570(7762):468-473. PubMed ID: 31142836
[TBL] [Abstract][Full Text] [Related]
32. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
[TBL] [Abstract][Full Text] [Related]
33. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.
Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N
Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130
[TBL] [Abstract][Full Text] [Related]
34. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
35. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
[TBL] [Abstract][Full Text] [Related]
36. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies.
McGuire AT; Dreyer AM; Carbonetti S; Lippy A; Glenn J; Scheid JF; Mouquet H; Stamatatos L
Science; 2014 Dec; 346(6215):1380-1383. PubMed ID: 25504724
[TBL] [Abstract][Full Text] [Related]
37. Strategies for a multi-stage neutralizing antibody-based HIV vaccine.
Andrabi R; Bhiman JN; Burton DR
Curr Opin Immunol; 2018 Aug; 53():143-151. PubMed ID: 29775847
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity Evaluation of N-Glycans Recognized by HIV Broadly Neutralizing Antibodies.
Shivatare SS; Cheng TR; Cheng YY; Shivatare VS; Tsai TI; Chuang HY; Wu CY; Wong CH
ACS Chem Biol; 2021 Oct; 16(10):2016-2025. PubMed ID: 34649433
[TBL] [Abstract][Full Text] [Related]
39. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?
Medina-Ramírez M; Sanders RW; Klasse PJ
Expert Rev Vaccines; 2014 Apr; 13(4):449-52. PubMed ID: 24606603
[TBL] [Abstract][Full Text] [Related]
40. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
Ahmad M; Ahmed OM; Schnepp B; Johnson PR
Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
